APA (7th ed.) Citation

BAIN, V. G., LEE, S. S., PELTEKIAN, K., YOSHIDA, E. M., DESCHÊNES, M., SHERMAN, M., . . . KRAJDEN, M. (2008). Clinical trial: Exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa-2a plus ribavirin. Alimentary Pharmacology & Therapeutics, 28(1), 43. https://doi.org/10.1111/j.1365-2036.2008.03705.x

Chicago Style (17th ed.) Citation

BAIN, V. G., et al. "Clinical Trial: Exposure to Ribavirin Predicts EVR and SVR in Patients with HCV Genotype 1 Infection Treated with Peginterferon Alfa-2a Plus Ribavirin." Alimentary Pharmacology & Therapeutics 28, no. 1 (2008): 43. https://doi.org/10.1111/j.1365-2036.2008.03705.x.

MLA (9th ed.) Citation

BAIN, V. G., et al. "Clinical Trial: Exposure to Ribavirin Predicts EVR and SVR in Patients with HCV Genotype 1 Infection Treated with Peginterferon Alfa-2a Plus Ribavirin." Alimentary Pharmacology & Therapeutics, vol. 28, no. 1, 2008, p. 43, https://doi.org/10.1111/j.1365-2036.2008.03705.x.